Riding the Revolution in Prostate Cancer Diagnosis & Treatment
Tomer Schatzberger
Chief Executive Officer
UC-CARE USA, Inc.
Confidential
The Problem Untargeted biopsies
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581822/
Miss nearly 40% of men with moderate/high grade disease (Gleason 7+)1
Patients move during biopsies due to discomfort - can lead to poor accuracy of biopsies
Increased risk of
• Repeat biopsies (~ 50%)
• Infection
• Delayed treatment C
C
CBlind 12-core needle biopsy
C
= Prostate Biopsy
B
B B
B
B
B
B
B
B
B
BB
= Cancer
B
Bladder
The ProblemBiopsy processing deficiencies
Up to 40% of tissue never analyzed2 due to • Fragmentation
• Tangling of cores
• Lost tissue during processing
Cannot identify exact cancer location within specimen leading to
• Unnecessary whole prostate treatment cost and complications
• Incontinence (diapers) and/or Impotence
Extremely high lab processing cost to put each specimen in individual jars
• One specimen/jar will still have inferior performance
2 2015 American Urology Association Conference Presentation
Prostate Cancer Market
1 in 6 men US annual statistics
1.5MBiopsy
procedures
175KMen diagnosed with prostate
cancer
32KMen
will die
Navigo MRI-Ultrasound Fusion System
• Fuses ultrasound (US) to MRI image for better targeting
• Targeted biopsies are 2-3X more sensitive for prostate cancer
• Insensitive to patient movement
• Provides biopsy & treatment guidance
SmartBxDisposable Cassette
• Safeguards specimen
• Pinpoints exact cancer location for treatment
• Saves lab time & cost
• Can be used with any fusion system
FDA-ClearedSolutions
SmartBx Disposable Cassette Opportunity for all soft tissue biopsies
Peer-Reviewed SmartBx DataBMC Urology (2019 19-23)
• 31% increase in detection of clinically significant high grade disease
• 30% increase in biopsy core length
• 95% reduction in biopsy fragmentation
Up to 50% lab cost savings
• 2 specimens processed at a time per cassette with less handling
SmartBx Standard Biopsy
Navigo Competitive AdvantagesOnly fusion system meeting needs of major medical centers as well as community sites
• Accurate. Real-time 3D biopsy localization & movement compensation; SmartBx
• Automated. Single person operation; automatic biopsy marking
• Affordable. Equipment, software, service, financing
Cancer
Targeted
Patients
• Want high detection• Want less invasive
treatment options• Avoid diapers and impotence
Pathologists
SmartBx• Improves biopsy quality > 25%
cancer detection + exact location • Reduces processing costs • Gains biopsy referrals
Navigo Fusion + SmartBx• Improves cancer detection• SmartBx unique localization enables
focal treatment/active surveillance • Attracts new patients
Urologists
Customer Triad
Traction: USA Users, Partners and PilotsAlready used in at least 13 U.S. states and multiple countries
SmartBx Global Annual Recurring Revenue •Prostate: $450M •Breast: $810M •All Soft Tissue: $2.7B
Fusion + MRI Software + Service : $1.5B+
Sources
Urology business development manager with BK Ultrasound
https://sperlingprostatecenter.com/mritrus-fusion-biopsies/
https://www.sec.gov/Archives/edgar/data/859737/000119312507145827/d425.htm
Patent Protection USA, Canada, Europe, Japan, China
Navigo and SmartBx Market Opportunity Summary
Navigo
• Proven Fusion need - ~400 units in leading US medical centers
- Only ~15% of market
• Community sites (~85%) face losing biopsy procedures > need Fusion
• Navigo offering ROI plus market-leading performance- Compatible with most available US
- Movement compensation, essential for
clinics
- Automation, one operator
SmartBx• For the Urologist
- Best localization- 25% detection improvement
• For the Path Lab- Can offer highest performance to Urologist
- Substantial cost reduction
• Compatible with any Fusion system (including the 400 installed units)
• No competition
Financials – 5 Year Plan
0
20
40
60
80
100
120
2019 2020 2021 2022 2023
Rev
enu
e in
Mill
ion
s
Recurring Disposable Capital
Q1 2021Breakeven
1.5
54.9
23.7
7.1
102.7
Leadership
Founder, Chairman & CEO
Shaike Schatzberger.
Chief Executive Officer
Tomer Schatzberger
Board Members
Prof. Yoram PaltiItzhak Shenberg, PhD
Director of U.S. Strategy
Kim StebbingsVP and COO
Galit Natan
UC-CARE Israel UC-CARE USA
The Ask
• Raising $10M including $3.5M CLA converted
• Use of Proceeds
• Grow USA Sales & Marketing
• R&D/Product: SmartBx for breast
• Mfg: Increase gross margins (90%)
Summary
• Very big market
• Revolution in prostate cancer treatment driving change
• Unique superior solution (Technology, Patents)
• Experienced team
• Winning business model
Tomer SchatzbergerCEO, UC-CARE, USA
UC-CARE Medical Systems Ltd. Yokneam, Israel and Tampa, FL
(813) 413-7147
www.uc-care.com